Cargando…

Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a high mortality rate worldwide. The percentage of HCC patients with vascular invasion at the time of initial HCC diagnosis is 10%–40%. According to most guidelines, HCC with vascular invasion is classified as advanced st...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zunyi, Zhang, Erlei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169581/
https://www.ncbi.nlm.nih.gov/pubmed/37180144
http://dx.doi.org/10.3389/fimmu.2023.1073531
_version_ 1785039068654993408
author Zhang, Zunyi
Zhang, Erlei
author_facet Zhang, Zunyi
Zhang, Erlei
author_sort Zhang, Zunyi
collection PubMed
description Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a high mortality rate worldwide. The percentage of HCC patients with vascular invasion at the time of initial HCC diagnosis is 10%–40%. According to most guidelines, HCC with vascular invasion is classified as advanced stage, and resection is only suggested for a minority of such patients. Recently, advances in systemic and locoregional treatments for such patients have resulted in amazing response rates. Therefore, a “conversion therapy” strategy including systemic and locoregional treatments is proposed to select patients from an initially unresectable state to eventually undergo R0 resection. Recently, many studies have proven that conversion therapy followed by subsequent surgery is achievable in well-selected advanced HCC patients and can provide prolonged long-term outcomes. Based on published research, this review has summarized the clinical experience and evidence of conversion treatment in HCC patients with vascular invasion.
format Online
Article
Text
id pubmed-10169581
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101695812023-05-11 Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review Zhang, Zunyi Zhang, Erlei Front Immunol Immunology Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a high mortality rate worldwide. The percentage of HCC patients with vascular invasion at the time of initial HCC diagnosis is 10%–40%. According to most guidelines, HCC with vascular invasion is classified as advanced stage, and resection is only suggested for a minority of such patients. Recently, advances in systemic and locoregional treatments for such patients have resulted in amazing response rates. Therefore, a “conversion therapy” strategy including systemic and locoregional treatments is proposed to select patients from an initially unresectable state to eventually undergo R0 resection. Recently, many studies have proven that conversion therapy followed by subsequent surgery is achievable in well-selected advanced HCC patients and can provide prolonged long-term outcomes. Based on published research, this review has summarized the clinical experience and evidence of conversion treatment in HCC patients with vascular invasion. Frontiers Media S.A. 2023-04-26 /pmc/articles/PMC10169581/ /pubmed/37180144 http://dx.doi.org/10.3389/fimmu.2023.1073531 Text en Copyright © 2023 Zhang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Zunyi
Zhang, Erlei
Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review
title Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review
title_full Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review
title_fullStr Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review
title_full_unstemmed Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review
title_short Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review
title_sort conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169581/
https://www.ncbi.nlm.nih.gov/pubmed/37180144
http://dx.doi.org/10.3389/fimmu.2023.1073531
work_keys_str_mv AT zhangzunyi conversiontherapyforadvancedhepatocellularcarcinomawithvascularinvasionacomprehensivereview
AT zhangerlei conversiontherapyforadvancedhepatocellularcarcinomawithvascularinvasionacomprehensivereview